Background
Alzheimer's disease (AD) is the most common cause of dementia in the United States [1] , but no effective therapies for treatment or prevention exist. Late-onset Alzheimer's disease (LOAD), defined by age-at-onset after 60 years, is the most common form of AD. Heritability estimates for LOAD stand at 60-80%, implicating genetics as an important factor in disease development [2] . While the APOE locus shows the strongest association [3] , LOAD is complex and polygenic [4] , and genome-wide association studies (GWAS) have successfully associated over 20 other genetic variants with LOAD [5, 6] . Recent studies have implicated a number of different biological processes in LOAD susceptibility such as microglial-mediated innate immunity [7] [8] [9] .
The majority of top GWAS variants reside in noncoding regions of the genome outside of protein-coding sequences [10] . Any variant in linkage disequilibrium (LD) with a top GWAS variant could be responsible for the association signal, and GWAS data alone lacks the granularity to identify these causal variants. In addition, noncoding variants variants with regulatory potential for diabetes [20, 21] and schizophrenia [22] , but such studies often assume that the relevant tissue context is known a priori.
We hypothesize that noncoding LOAD GWAS signals modulate disease risk by perturbing genomic elements that regulate genes involved in pathogenesis. To explore this hypothesis, we applied our bioinformatics pipeline, INFERNO (INFERring the molecular mechanisms of NOncoding genetic variants) [23] to LOAD GWAS data from the International Genomics of Alzheimer's Project (IGAP) [6] . INFERNO characterizes noncoding GWAS signals by integrating information across diverse functional genomics data sources to identify causal noncoding variants and the regulatory mechanisms, tissue contexts, and target genes they affect (Figure 1a ). INFERNO identified several putatively causal genetic variants in ten GWAS regions and uncovered strong functional evidence of their effects on immune-and brain-related regulatory mechanisms. Using luciferase reporter assays, we validated the enhancer activity and allelic differences of causal variants in three regions prioritized by relevant tissue context, strength of annotation support, and prior literature.
Methods

INFERNO analysis of IGAP top hits
INFERNO (details of the algorithm are described in [23] ) was used to analyze 19 top variants from Phase 1 of the IGAP study, excluding the locus near DSG2 (tagged by rs8093731) which did not replicate in Phase 2 and the HLA-DRB5 locus (rs9271192) which is difficult to analyze due to the dense LD structure in the major histocompatibility (MHC) region caused by population-specific selective pressure [24] . INFERNO was run using P value expansion within one order of magnitude and 500 kilobases (kb) of each tagging variant, and the European population from the 1,000 Genomes Project [25] was used for LD pruning and expansion. For both pruning and expansion, a threshold of r 2 >= 0.7 was used to define LD blocks. All downstream analyses including lncRNA correlation and pathway analysis were performed as defined in [23] .
Luciferase validation
Through molecular cloning techniques, insert sequences including the enhancers (800-1,739 base pairs (bp) in length, Supplementary Table 1 ) overlapping each prioritized variant were placed upstream of a minimal promoter and a luciferase reporter gene in a pGL vector. Two different vectors were generated for each prioritized variant: one with the minor allele of the prioritized variant and one with the major allele. Additionally, we generated vectors containing a minimal promoter with no enhancer inserted and another negative control vector with a minimal promoter and a ~1kb random genomic heterochromatin insert. 300ng of each vector was mixed with one-tenth the amount of a Renilla expressing vector, allowing us to normalize Luciferase expression for transfection efficiency. This mixture was transfected into separate aliquots of K562 cells using the Lonza Nucleofector Device with Kit V. A mock sample was run through the same transfection procedure with no DNA to account for background luminescence.
The Promega Dual-Glo system was used to measure Luciferase and Renilla expression. Background-subtracted Luciferase luminescence levels were divided by the corresponding background-subtracted Renilla luminescence, and all ratios were normalized to the average of the minimal promoter condition for quantitative analysis. A total of n = 5 biological replicate experiments were carried out, each including 4 technical replicates per condition.
Statistical analysis was performed using a linear mixed model treating experimental days as random effects and alleles as fixed effect using the lmerTest package [26] in R v3.4.4 [27] . P values for the comparisons between conditions were obtained by analysis of variance (ANOVA) using Satterthwaite's approximation for degrees of freedom.
Results
Expansion and annotation of IGAP loci
To identify genetic variants with regulatory potential for LOAD, we used INFERNO to analyze the 19 genome-wide significant loci from Phase I of IGAP ( Figure 1a , Table 1 ) [6] . The region tagged by each top variant is referred to by the name of the nearest gene by convention, although these genes are not necessarily causal for the association signals. For each top variant, we identified all variants within 500kb that had a P value within an order of magnitude and the same minor allele effect direction. We pruned these p-value expanded sets by LD into independent variants, which we reexpanded yielding 1,044 unique potentially causal variants (Table 1) Next, we overlapped these variants with enhancers defined by bidirectional enhancer RNA (eRNA) transcription in 112 tissues and cell types from the FANTOM5 consortium [17] and by the ChromHMM epigenomic state-based method [28] in 127 tissues and cell types from the Roadmap Epigenomics Project [15, 29, 30] . This identified 38 variants overlapping FANTOM5 enhancers in 9 tag regions ( Table 1 ). The FANTOM5 tissue with the most enhancer-overlapping variants was monocytes, with 25 overlapping variants, whereas the brain harbored only 6 variants ( Supplementary Figure 1a ). For the Roadmap data, variants were overlapped with a total of 15 ChromHMM states including 3 types of enhancer states (enhancers, genic enhancers, and bivalent enhancers). 652 unique variants representing all 19 tag regions were found to overlap a ChromHMMdefined enhancer state in at least one tissue ( Table 1 ). Like the FANTOM5 results, primary monocytes from peripheral blood had the most overlapping variants (149 unique variants, Supplementary Figure 1b ), but 146 unique variants overlapped enhancers in at least one of the brain-related Roadmap datasets.
We also used INFERNO to find variants affecting transcription factor binding sites 
Integrative analysis of enhancer enrichment patterns
Using INFERNO's tissue categorization approach [23] that groups each functional genomics dataset into one of 32 high-level tissue categories, we identified 36 variants from nine tag regions (the CASS4, CELF1, EPHA1, FERMT2, MS4A6A, NME8, PICALM, PTK2B, and SLC24A4/RIN3 regions) that overlapped concordant FANTOM5 and Roadmap ChromHMM enhancers in a tissue category (Figure 2a ). All of these regions harbored at least one variant with concordant support in the blood category, supporting the hypothesis of immune mechanisms underlying LOAD genetic signals [7] [8] [9] . The CELF1 region was the only one to harbor variants with concordant overlaps of brain enhancers, supporting the unbiased approach of not requiring an a priori hypothesis of relevant tissue context. Many variants overlapped FANTOM5 enhancers in the blood category, which included all the immune-related cell lines such as monocytes and macrophages in addition to whole blood (Supplementary Figure 3a ). All 22 of the tissue categories sampled by the Roadmap Epigenomics consortium contained ChromHMM-defined enhancer-related states that harbored at least one variant in the expanded set ( Supplementary Figure 3b ). Again, many variants overlapped Roadmap enhancers in the blood category.
INFERNO includes a method to statistically quantify the enrichments of variants overlapping FANTOM5 enhancers, Roadmap enhancers, or both in each tissue category. This revealed significant enrichments of variants overlapping both FANTOM5 and concordant enhancers in the blood category and a significant enrichment of Roadmap enhancers in the brain category ( Figure 2b ) as well as several other enrichments including in the connective tissue category, which contains fibroblasts.
Co-localization analysis with GTEx eQTLs
To identify target genes affected by dysregulated enhancers, INFERNO uses expression quantitative trait loci (eQTLs) -variants whose alleles are correlated with differing levels of a target gene -from the Genotype-Tissue Expression (GTEx) project [16] across 44 tissues. Of the 1,044 potentially causal variants, 750 were significant eQTLs in at least one tissue. However, due to dense LD structures in many of our significant regions, this direct overlap approach may yield false positive variants in LD with the truly causal eQTL variant. To address this issue, INFERNO incorporates a Bayesian statistical model (COLOC [32] ) to identify co-localized GWAS/eQTL signals with shared causal variants, quantified as the posterior probability P(H 4 ). The COLOC method also computes the probability of any individual variant being the shared causal variant, quantified as their Approximate Bayes Factors (ABFs).
We applied COLOC to tissue-specific eQTL signals for 884 unique genes across all 19 tag regions (median number of genes within each region = 34) for 25,435 tests of GWAS -tissue-specific eQTL co-localization ( Supplementary Figure 4a , Methods). We identified 153 co-localized GWAS/eQTL signals (P(H 4 ) >= 0.5 representing strong support for a shared causal signal [23] ) representing 16 tag regions, 37 tissues and 71 target genes ( Supplementary Figure 4b ). For 32 of these, COLOC identified individual variants with ABF >= 0.5, but in the majority of cases COLOC was not able to prioritize a single causal variant. This is likely caused by dense LD structures where GWAS and eQTL signals are dispersed across all variants in the LD block (Supplementary Figure   4c ). Thus, for each co-localized GWAS/eQTL signal we sampled the highest ABF variants until their sum was 0.5 or greater ( Supplementary Figure 4d , [23] ). Across the 153 co-localized signals, this yielded 1,291 unique variant-tissue-target gene relationships accounted for by 286 unique variants, 182 of which were in the LDexpanded set.
Comparison of enhancer overlaps with eQTL co-localization signals
We next used the INFERNO tissue categorizations to stratify variants in the ABFexpanded sets by whether they affected a TFBS, overlapped any enhancer, and whether the enhancer came from the same tissue category as the eQTL (Figure 2c ).
For the first stage of variant prioritization, we considered only variants overlapping concordant enhancers, and took two approaches for further prioritization: requiring TFBS overlap (TBFS prioritization) and requiring ABF >= 0.5 (ABF prioritization). TFBS prioritization identified 43 unique variant-tissue-gene sets (20 unique variants across 8 tag regions, Figure 2d , top row) including 15 in the brain or blood categories. ABF prioritization prioritized 14 variant-tissue-gene sets (6 unique variants across 5 tag regions, Figure 2d , left column), including 2 variants which also had motif overlaps.
Together, these two approaches identified potentially causal variants in 10 tag regions ( Table 2 , Supplementary Tables 1-2 ). We prioritized four of these signals for experimental validation based on prior literature, strength of annotation support, and relevant tissue contexts: EPHA1, CD33, BIN1, and CD2AP.
EPHA1 region functional variant upregulates lncRNA affecting the JAK2 signaling axis
The strongest signal by both annotation and ABF evidence was in the EPHA1 region, where the variant rs11765305 had an ABF of 0.999 underlying an eQTL for the EPHA1-AS1 antisense long non-coding RNA (lncRNA) in whole blood (P(H 4 ) = 0.516). This variant also colocalized with whole blood eQTLs for the TAS2R60 taste receptor gene (P(H 4 ) = 0.516, ABF = 1.00) and the TAS2R62P taste receptor gene (P(H 4 ) = 0.537, ABF = 0.714) (Supplementary Table 1 ). rs11765305 overlapped FANTOM5 and Roadmap enhancers in the blood category, including white blood cells in the myeloid lineage such as monocytes and macrophages (Figure 3a ), and creates a stronger binding site for CEBPB (∆PWM score = 1.53), an enhancer-binding transcription factor that is associated with immune-related gene regulation [33] . This increase in TF binding is consistent with the positive effect of the rs11765305 minor allele on EPHA1-AS1 expression observed in GTEx (β = 1.25, where a ß greater than 1 reflects an increase in gene expression).
To compare enhancer activity between the major and minor alleles of rs11765305, we performed luciferase assays in K562 leukemia cells, which are from the same myeloid cell lineage as monocytes. Although the major allele had no significant luciferase expression compared to controls, the minor allele had significantly higher expression compared to both controls and the major allele ( Figure 3b ). These results confirm the predicted monocyte enhancer activity in this region and are consistent with the mechanism that the minor allele of rs11765305 creates a stronger CEBPB TFBS, increasing the activity of an enhancer regulating EPHA1-AS1, TAS2R60, and
TAS2R62P.
We next set out to identify the downstream effects of EPHA1-AS1, as lncRNAs can modulate gene expression through recruitment of regulatory proteins or binding to target transcripts [34] . INFERNO uses GTEx RNA-seq data to identify genes whose expression is correlated with that of a lncRNA using a threshold of 0.5 on both Pearson and Spearman correlations across 44 tissues [23] . For EPHA1-AS1, this yielded one gene, JAK2 (Pearson r 2 = 0.517, Spearman r 2 = 0.582) ( Figure 3c ). JAK2 is part of the JAK2/STAT3 signaling axis, whose disturbance by amyloid-ß leads to memory impairment [35] . The tag variant in this region is protective and rs11765305 has the same effect direction, so INFERNO prioritized a mechanism whereby the protective minor allele of rs11765305 increases EPHA1-AS1 expression which in turn increases the activity of the JAK2/STAT3 signaling axis, implying that JAK2/STAT3 activation may protect against LOAD.
Functional validation of blood regulation of CD33
In the CD33 region, COLOC identified co-localized GWAS/eQTLs for CD33 itself in whole blood (P(H 4 ) = 0.955) and for AC018755.1 (P(H 4 ) = 0.683) in brain hypothalamus.
In both cases, rs12459419 was prioritized by concordant enhancer and motif overlap.
However, the tag variant rs3865444 had a higher ABF in both cases (0.491 and 0.489, respectively). rs3865444 overlaps Roadmap enhancers in 6 cell lines including primary monocytes and primary T regulatory cells from peripheral blood. In contrast, rs12459419 only overlapped Roadmap enhancers from 3 cell lines including primary T regulatory cells from peripheral blood and fetal brain but lacked the monocyte enhancer overlap ( Supplementary Table 1 ). Additionally, rs3865444 has been extensively studied, with previous work showing that the protective minor allele (A) decreases the levels of CD33 protein [36] , decreases CD33 mRNA expression consistent with the direction of the GTEx eQTL effect (β = 0.352) [37] , and reduces cell surface expression of CD33 in monocytes [38] .
Based on the prior literature, the strong ABF signal, and the monocyte enhancer overlap, we analyzed rs3865444 in our luciferase assays. This found significant increases for the major allele and significant decreases for the minor allele relative to the controls, as well as a striking decrease in enhancer activity of the minor allele relative to the major allele (Figure 4a ). This was consistent with prior reports and the GTEx eQTL direction for this variant (ß = 0.352).
Functional validation of lymphocyte regulation of BIN1
In the BIN1 region, INFERNO identified a co-localized GWAS/eQTL for BIN1 in EBVtransformed lymphocytes (P(H 4 ) = 0.652) with the variant rs4663105 prioritized by ABF (ABF = 0.777). This variant overlaps Roadmap enhancers in primary monocyte cells and placenta but does not overlap any TFBSs. rs4663105 has been previously associated with LOAD risk, and an insertion in that region was associated with increased BIN1 expression [39] . This previous study found no difference in luciferase activity between the two alleles of rs4663105 in SKNSH-SY5Y and HEK cells. However, their construct only spanned 60bp around the variant, whereas the monocyte enhancer is 800bp. Therefore, we cloned the full Roadmap enhancer region (Supplementary Table 1 ) for luciferase assays in K562 cells, which are more relevant to the functional annotations in this region. This found significantly increased enhancer activity for both alleles of rs4663105 relative to the control vectors, and a slight but significant decrease of the minor allele relative to the major allele (p = 0.0328, Figure 4b ), consistent with the direction of the GTEx eQTL (ß = 0.496). [40, 41] . CD2AP encodes a scaffolding molecule that regulates the actin cytoskeleton and is involved in endocytic processes [42] , while RP11-385F7.1 is a lncRNA near the promoter for the CD2AP gene.
CD2AP region variants
We performed luciferase assays, but both alleles of rs9367279 had significantly decreased enhancer activity relative to the controls, and there was no strong difference between the two alleles, suggesting that this enhancer may not be active in K562 cells (Figure 4c , p = 0.1892). RP11-385F7.1 was strongly correlated with 64 transcripts (Figure 4d, Supplementary Table 4 ), and we performed pathway analysis of these targets using the WebGestalt tool [43, 44] to interpret the increased number of targets relative to section 3.5, but found no enrichments after controlling for false discovery rate. The gene with the strongest Pearson correlation was PPP1R16A (Pearson r 2 = 0.641, Spearman r 2 = 0.593) and the gene with the strongest Spearman correlation was COQ4 (Pearson r 2 = 0.608, Spearman r 2 = 0.660). PPP1R16A, also known as MYPT3, directs the protein phosphatase PP1c to its targets and is involved in actin binding and G-protein coupled receptor pathways [45] . COQ4 is part of the coenzyme Q biosynthesis pathway, an antioxidant that may modify LOAD-associated oxidative damage [46] . The eQTL effects of rs9367279 on RP11-385F7.1 are weak and inconsistent between the two brain regions (ß = 0.969 in cerebellar hemisphere and 1.194 in cerebellum), suggesting that rs9367279 contributes to fine-scale regulation of RP11-385F7.1 in brain, although it has a relatively strong repressive effect on CD2AP in fibroblasts (ß = 0.505).
Discussion
Our application of INFERNO to LOAD GWAS data prioritized perturbations of tissuespecific regulatory mechanisms in 10 IGAP tag regions ( Table 2 , Supplementary Table   3 ). In the EPHA1, CD2AP, CELF1, and CASS4 regions, the target genes of the colocalized GWAS/eQTL signals included lncRNAs, so identifying affected enhancers and target genes may be only the first step towards understanding genetic effects on regulatory networks contributing to disease pathogenesis. The tissue classification approach implemented in INFERNO also enabled the unbiased investigation of the relevant tissue contexts affected by each genetic signal. Limiting our analysis to only brain datasets would have missed the blood-category signals that we detected. These immunity-related signals are in line with other recent work highlighting neuroinflammation as a crucial component of LOAD pathogenesis and etiology [7] [8] [9] .
INFERNO did not identify regulatory mechanisms in all 19 of the IGAP regions, and this may be driven by several aspects of this analysis. We are limited by the sample sizes and sets of tissues that were assayed by the FANTOM5, Roadmap, and GTEx consortia and the number of datasets that went into each tissue category, with some categories being much more sparsely sampled than others [23] . Another consideration is that this regulatory analysis focused on transcriptional enhancers, but it is possible that the noncoding signals in the unexplained tag regions affect other regulatory mechanisms such as small noncoding RNA (sncRNA) loci. Previous studies implicated sncRNA dysregulation in LOAD pathogenesis [47] , suggesting that this will be a fruitful approach for future analysis efforts.
In conclusion, our application of INFERNO to IGAP GWAS data yielded insights into the regulatory mechanisms affected by noncoding LOAD-associated genetic variants.
Experimental validation supported our computationally predicted regulatory effects, suggesting that our approach is able to prioritize truly causal regulatory mechanisms at GWAS loci for post-GWAS experiments. Incorporating more functional genomics data as it is generated in concert with more refined validation experiments using a broader range of cell types and molecular techniques will yield insights into a range of phenotypes. Author contributions 
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